Skip to content
10-Q

Quarterly Report

Stoke Therapeutics, Inc. STOK

0001193125-26-211874

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 62.28M sh
Shares Diluted Q1 2026 · Mar 31, 2026 63.06M sh
Shares Diluted Q1 2026 · Mar 31, 2025 59.4M sh
Capex Q1 2026 · Mar 31, 2026 $353K
Capex Q1 2026 · Mar 31, 2025 $152K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$60.58M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $131.83M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $155.66M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $84.22M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $274.82M
Stockholders Equity Q1 2026 · Mar 31, 2026 $394.88M
Stockholders Equity Q1 2026 · Dec 31, 2025 $352.46M
Stockholders Equity Q1 2026 · Mar 31, 2025 $350.07M
Stockholders Equity Q1 2026 · Dec 31, 2024 $229.02M
Current Liabilities Q1 2026 · Mar 31, 2026 $40.81M
Current Liabilities Q1 2026 · Dec 31, 2025 $57.88M
Total Liabilities Q1 2026 · Mar 31, 2026 $48.4M
Total Liabilities Q1 2026 · Dec 31, 2025 $65.98M
Current Assets Q1 2026 · Mar 31, 2026 $366.68M
Current Assets Q1 2026 · Dec 31, 2025 $305.7M
Total Assets Q1 2026 · Mar 31, 2026 $443.28M
Total Assets Q1 2026 · Dec 31, 2025 $418.43M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.79
Eps Diluted Q1 2026 · Mar 31, 2025 $1.90
Eps Basic Q1 2026 · Mar 31, 2026 −$0.79
Eps Basic Q1 2026 · Mar 31, 2025 $1.95
Sga Expense Q1 2026 · Mar 31, 2026 $19.97M
Sga Expense Q1 2026 · Mar 31, 2025 $14.65M
Rd Expense Q1 2026 · Mar 31, 2026 $39.67M
Rd Expense Q1 2026 · Mar 31, 2025 $32.68M
Net Income Q1 2026 · Mar 31, 2026 −$50M
Net Income Q1 2026 · Mar 31, 2025 $112.88M
Operating Income Q1 2026 · Mar 31, 2026 −$53.42M
Operating Income Q1 2026 · Mar 31, 2025 $111.24M
Revenue Q1 2026 · Mar 31, 2026 $6.23M
Revenue Q1 2026 · Mar 31, 2025 $158.57M